Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid noted for its anti-inflammatory and anti-proliferative properties. It is effective in reducing atherosclerosis in apolipoprotein E-deficient mice, a commonly used model for studying this condition[1].[2].[3].
体内研究
In cancer research, DGLA at a dosage of 8 mg per mouse, administered intragastrically twice a week for 35 days, has been effective in suppressing the growth of xenograft tumors in mice implanted with human pancreatic cancer cells (BxPC-3) that have been transfected with delta-5-desaturase shRNA, highlighting its potential therapeutic applications in oncology[3].
体外研究
DGLA also reduces the expression of pro-inflammatory genes in human and mouse macrophages[2].
Specifically, when administered at a concentration of 50 μM for 24 hours, DGLA lessens the phosphorylation of STAT1 on serine 727 induced by IFN-γ[2].
Dihomo-γ-linolenic acid also diminishes the expression of MCP-1 and ICAM-1, which are induced by IL-1β and TNF-α, in human macrophages[2].
Furthermore, DGLA has been shown to inhibit chemokine-driven monocytic migration and the formation of macrophage foam cells, which are key processes in the development of atherosclerosis[2].
搜索
